Vision Capital Management Inc. Increases Holdings in Johnson & Johnson (NYSE:JNJ)

Vision Capital Management Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,698 shares of the company's stock after buying an additional 2,412 shares during the quarter. Johnson & Johnson comprises about 1.4% of Vision Capital Management Inc.'s investment portfolio, making the stock its 17th biggest holding. Vision Capital Management Inc.'s holdings in Johnson & Johnson were worth $9,569,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Lantz Financial LLC raised its stake in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after buying an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. purchased a new position in shares of Johnson & Johnson in the fourth quarter worth $453,000. Joel Isaacson & Co. LLC increased its holdings in Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after buying an additional 2,526 shares in the last quarter. State of Wyoming raised its position in Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after buying an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC lifted its stake in Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after acquiring an additional 2,529 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.5%

NYSE JNJ opened at $156.87 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $377.44 billion, a P/E ratio of 17.45, a price-to-earnings-growth ratio of 2.15 and a beta of 0.41. The stock's 50-day moving average price is $153.75 and its 200-day moving average price is $154.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.31%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Barclays reduced their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Bank of America cut their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Royal Bank Of Canada restated an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Finally, Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $171.00.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.